Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update
Ultragenyx (NASDAQ: RARE) will host a conference call at 5:00 p.m. ET on Thursday, February 12, 2026 to discuss fourth-quarter and full-year 2025 financial results and a corporate update.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ultragenyx (NASDAQ: RARE) will host a conference call at 5:00 p.m. ET on Thursday, February 12, 2026 to discuss fourth-quarter and full-year 2025 financial results and a corporate update. A live webcast and replay will be available via the company investor website.
The replay will remain available for three months following the call.
Details
News Market Reaction – RARE
On Feb 6, the first trading day after this news, RARE closed 3.83% above the previous close.
Data tracked by StockTitan Argus for the Feb 6 session.
Key Figures
- Conference call time
- 5:00 p.m. ET
- Scheduled for February 12, 2026
- Call date
- February 12, 2026
- Covers Q4 and full-year 2025 results
- Fiscal year end
- December 31, 2025
- Period to be discussed on the call
- Replay availability
- Three months
- Duration replay will remain on company website
Previous Conferences,earnings Reports
-
Announced Q3 2025 results call and webcast access details.
-
Scheduled Q2 2025 conference call to review financials and updates.
-
Set date and time for Q1 2025 financial results call.
-
Announced Q4 and full-year 2024 results conference call.
-
Planned Q3 2024 financial results and corporate update call.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NOVATO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Thursday, February 12, 2026, to discuss its financial results and corporate update for the quarter and the year ending December 31, 2025.
The live and replayed webcast of the call will be available through the company’s website at https://ir.ultragenyx.com/events-presentations. The replay of the call will be available for three months.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contact Ultragenyx
Investors
Joshua Higa
ir@ultragenyx.com
Media
Jess Rowlands
media@ultragenyx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.